# Navigating Cancer

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/navigating-cancer

- Industry: Healthcare IT
- Headquarters: Seattle, US
- Website: www.navigatingcancer.com/
- Total disclosed funding: $31M
- Latest round: Series D (Sep 17, 2019)
- Investors on record: 6

## About

Founded in 2008 and based in Washington, US, Navigating Cancer, Inc. owns and operates an online platform for cancer patients and their supporters. In September 2024, OneOncology, LLC, a portfolio company of Frist Cressey Ventures, acquired Navigating Cancer, Inc. from Rustic Canyon Partners, Western Technology Investment, Merck Global Health Innovation Fund, ORIX Corporation, BrightEdge Ventures, Laboratory Corporation of America Holdings, and TT Capital Partners. As of 2024, the company is led by its CEO, Bill Bunker.

The company provides a patient management platform that integrates with electronic health records (EHRs) to streamline workflows, reduce costs, and support better health outcomes. The firm’s platform offers digital triage, electronic patient-reported outcomes (ePRO), and patient engagement solutions that empower patients to actively participate in their care. Navigating Cancer’s offerings include a secure patient engagement portal with two-way messaging, personalized education for different stages of treatment, and remote monitoring to provide a clinic-at-home experience. In addition, the company’s digital triage pathways and symptom management tools enhance communication between patients and care teams, ensuring timely responses and better symptom control. The firm’s solutions are designed to amplify the efficiency of healthcare providers and improve patient quality of life, with a focus on optimizing staff efficiency and reducing the burden of cancer care.

## Funding rounds

- Series D, Sep 17, 2019, $14M — Rustic Canyon Partners, ORIX Growth Capital, Merck Global Health Innovation Fund, Laboratory Corporation of America Holdings, TT Capital Partners, BrightEdge Ventures
- Series D, Apr 1, 2019, $12M — Rustic Canyon Partners, ORIX Growth Capital, Merck Global Health Innovation Fund
- Series B, Oct 27, 2011, $3M — Rustic Canyon Partners
- Series A, Jun 1, 2009, $2M — Rustic Canyon Partners

## Investors

- Rustic Canyon Partners (https://capitalatlas.ai/funds/rustic-canyon-partners) — Series A, Series B, Series D
- ORIX Growth Capital — Series D
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series D
- Laboratory Corporation of America Holdings — Series D
- TT Capital Partners — Series D
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series D